Psoriasis and Psoriatic Arthritis Educational Initiatives: An Update from the 2013 GRAPPA Annual Meeting

REFERENCES

1. 1.↵
   1. Callis Duffin K,
   2. Mease PJ

   . Psoriasis and psoriatic arthritis video project 2010: a report from the GRAPPA annual meeting. J Rheumatol 2011;38:562–3.

   OpenUrlAbstract/FREE Full Text
2. 2.↵
   1. Woodcock JL,
   2. Mease PJ,
   3. Callis Duffin K

   . Psoriasis and psoriatic arthritis video project: an update from the 2010 GRAPPA annual meeting. J Rheumatol 2012;39:421–2.

   OpenUrlAbstract/FREE Full Text
3. 3.↵
   1. Callis Duffin K,
   2. Armstrong AW,
   3. Mease PJ

   . Psoriasis and psoriatic arthritis video project: an update from the 2012 GRAPPA annual meeting. J Rheumatol 2013;40:1455–6.

   OpenUrlAbstract/FREE Full Text
4. 4.↵
   1. Fredriksson T,
   2. Pettersson U

   . Severe psoriasis—oral therapy with a new retinoid. Dermatologica 1978;157:238–44.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Finlay AY

   . Current severe psoriasis and the rule of tens. Br J Dermatol 2005;152:861–7.

   OpenUrlCrossRefPubMed
6. 6.↵
   1. Armstrong AW,
   2. Parsi K,
   3. Schupp CW,
   4. Mease PJ,
   5. Duffin KC

   . Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters. JAMA Dermatol 2013;149:577–82.

   OpenUrlCrossRefPubMed
7. 7.
   1. Thomas CL,
   2. Finlay AY

   . The ‘handprint’ approximates to 1% of the total body surface area whereas the ‘palm minus the fingers’ does not. Br J Dermatol 2007;157:1080–1.

   OpenUrlCrossRefPubMed
8. 8.
   1. Carlin CS,
   2. Callis KP,
   3. Krueger GG

   . Efficacy of acitretin and commercial tanning bed therapy for psoriasis. Arch Dermatol 2003;139:436–42.

   OpenUrlCrossRefPubMed
9. 9.
   1. Leonardi CL,
   2. Powers JL,
   3. Matheson RT,
   4. Goffe BS,
   5. Zitnik R,
   6. Wang A,
   7. et al.

   Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014–22.

   OpenUrlCrossRefPubMed
10. 10.
    1. Krueger GG,
    2. Langley RG,
    3. Leonardi C,
    4. Yeilding N,
    5. Guzzo C,
    6. Wang Y,
    7. et al.

    A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580–92.

    OpenUrlCrossRefPubMed
11. 11.
    1. Cappelleri JC,
    2. Bushmakin AG,
    3. Harness J,
    4. Mamolo C

    . Psychometric validation of the physician global assessment scale for assessing severity of psoriasis disease activity. Qual Life Res 2013;22:2489–99.

    OpenUrlCrossRefPubMed
12. 12.
    1. Rich P,
    2. Scher RK

    . Nail Psoriasis Severity Index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003;49:206–12.

    OpenUrlCrossRefPubMed
13. 13.
    1. Cassell SE,
    2. Bieber JD,
    3. Rich P,
    4. Tutuncu ZN,
    5. Lee SJ,
    6. Kalunian KC,
    7. et al.

    The modified Nail Psoriasis Severity Index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007;34:123–9.

    OpenUrlAbstract/FREE Full Text
14. 14.
    1. Katsambas A,
    2. Peris K,
    3. Vena G,
    4. Freidmann P,
    5. Wozel G,
    6. Dauden E,
    7. et al.

    Assessing the impact of efalizumab on nail, scalp and palmoplantar psoriasis and on quality of life: results from a multicentre, open-label, phase IIIb/IV trial. Arch Drug Inf 2009;2:66–70.

    OpenUrlCrossRefPubMed
15. 15.
    1. Bhushan M,
    2. Burden AD,
    3. McElhone K,
    4. James R,
    5. Vanhoutte FP,
    6. Griffiths CE

    . Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2001;145:546–53.

    OpenUrlCrossRefPubMed
16. 16.
    1. Ports WC,
    2. Khan S,
    3. Lan S,
    4. Lamba M,
    5. Bolduc C,
    6. Bissonnette R,
    7. et al.

    A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis. Br J Dermatol 2013;169:137–45.

    OpenUrlCrossRefPubMed
17. 17.
    1. Helliwell PS,
    2. Firth J,
    3. Ibrahim GH,
    4. Melsom RD,
    5. Shah I,
    6. Turner DE

    . Development of an assessment tool for dactylitis in patients with psoriatic arthritis. J Rheumatol 2005;32:1745–50.

    OpenUrlAbstract/FREE Full Text
18. 18.
    1. Mease PJ,
    2. Antoni CE,
    3. Gladman DD,
    4. Taylor WJ

    . Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 Suppl 2:ii49–54.

    OpenUrlAbstract/FREE Full Text
19. 19.
    1. Gladman DD,
    2. Inman RD,
    3. Cook RJ,
    4. van der Heijde D,
    5. Landewe RB,
    6. Braun J,
    7. et al.

    International spondyloarthritis interobserver reliability exercise—the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007;34:1733–9.

    OpenUrlAbstract/FREE Full Text
20. 20.
    1. Gladman DD,
    2. Inman RD,
    3. Cook RJ,
    4. Maksymowych WP,
    5. Braun J,
    6. Davis JC,
    7. et al.

    International spondyloarthritis interobserver reliability exercise—the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007;34:1740–5.

    OpenUrlAbstract/FREE Full Text